Latest & greatest articles for rivaroxaban

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rivaroxaban or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rivaroxaban and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rivaroxaban

21. The Efficacy of Combined Use of Rivaroxaban and Tranexamic Acid on Blood Conservation in Minimally Invasive Total Knee Arthroplasty a Double-Blind Randomized, Controlled Trial

The Efficacy of Combined Use of Rivaroxaban and Tranexamic Acid on Blood Conservation in Minimally Invasive Total Knee Arthroplasty a Double-Blind Randomized, Controlled Trial 27663190 2016 09 24 2017 02 13 1532-8406 32 3 2017 Mar The Journal of arthroplasty J Arthroplasty The Efficacy of Combined Use of Rivaroxaban and Tranexamic Acid on Blood Conservation in Minimally Invasive Total Knee Arthroplasty a Double-Blind Randomized, Controlled Trial. 801-806 S0883-5403(16)30522-8 10.1016/j.arth (...) .2016.08.020 Tranexamic acid (TXA) was reportedly to decrease postoperative blood loss after standard total knee arthroplasty (TKA). However, the blood-conservation effect of TXA in minimally invasive TKA, in particular, receiving a direct oral anticoagulant was unclear. The aim of the study was to investigate the efficacy of combined use of TXA and rivaroxaban on postoperative blood loss in primary minimally invasive TKA. In a prospective, randomized, controlled trial, 198 patients were assigned

EvidenceUpdates2016

22. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States

Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States 27550177 2016 09 07 2017 02 20 1742-1241 70 9 2016 Sep International journal of clinical practice Int. J. Clin. Pract. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States. 752-63 (...) 10.1111/ijcp.12863 Limited data are available about the real-world safety of non-vitamin K antagonist oral anticoagulants (NOACs). To compare the major bleeding risk among newly anticoagulated non-valvular atrial fibrillation (NVAF) patients initiating apixaban, warfarin, dabigatran or rivaroxaban in the United States. A retrospective cohort study was conducted to compare the major bleeding risk among newly anticoagulated NVAF patients initiating warfarin, apixaban, dabigatran or rivaroxaban

EvidenceUpdates2016 Full Text: Link to full Text with Trip Pro

23. Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis?

Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis? 28717737 2018 11 13 2378-9506 3 1 2017 Feb Journal of global oncology J Glob Oncol Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis? 15-22 10.1200/JGO.2015.002527 Venous thromboembolic events (VTEs) are common and potentially fatal complications in cancer patients, and they are responsible for the second most common cause of death. Low molecular weight heparin (LMWH) is the gold (...) -standard treatment, but the costs involved limit its use, especially in developing countries. Recently, the oral anticoagulant rivaroxaban, which directly inhibits factor Xa, was approved for VTE treatment. We conducted a retrospective analysis from January 2009 to February 2014 with patients who had cancer and VTE who were receiving rivaroxaban. We compared the efficacy, safety, and cost of rivaroxaban and low molecular weight heparin (LMWH) alone or followed by vitamin K antagonists. Forty-one

Journal of global oncology2016 Full Text: Link to full Text with Trip Pro

24. Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban-treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding

Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban-treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding 26765080 2016 02 09 2016 09 14 2017 02 20 1553-2712 23 2 2016 Feb Academic emergency medicine : official journal of the Society for Academic Emergency Medicine Acad Emerg Med Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban-treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding. 144-50 10.1111/acem.12865 Outpatient (...) treatment of acute venous thromboembolism (VTE) requires the selection of patients with a low risk of bleeding during the first few weeks of anticoagulation. The accuracy of four systems, originally derived for predicting bleeding in VTE treated with vitamin K antagonists (VKAs), was assessed in VTE patients treated with rivaroxaban. All patients treated with rivaroxaban in the multinational EINSTEIN deep vein thrombosis (DVT) and pulmonary embolism (PE) trials were included. Major bleeding was defined

EvidenceUpdates2016 Full Text: Link to full Text with Trip Pro

25. Unplanned pregnancy on a direct oral anticoagulant (Rivaroxaban): A warning

Unplanned pregnancy on a direct oral anticoagulant (Rivaroxaban): A warning 27512489 2016 08 11 2018 11 13 1753-495X 9 1 2016 Mar Obstetric medicine Obstet Med Unplanned pregnancy on a direct oral anticoagulant (Rivaroxaban): A warning. 40-2 10.1177/1753495X15621814 Direct oral anticoagulants (DOACs or NOACs -non-vitamin K oral anticoagulants), as the name suggests, are oral anticoagulants with a direct inhibitory action either against factor X or factor II (thrombin). Pregnant women were (...) excluded from participating in all the large trials of the DOACs and they are considered contra-indicated in pregnancy and breast feeding. We present a case of inadvertent exposure to rivaroxaban in a woman who presented at 25 weeks' gestation. The management of her pregnancy and delivery is described, and the previous published case reports are reviewed with a discussion about the use of DOACs in woman of childbearing age. Myers B B Department of Haematology, Leicester Royal Infirmary, Leicester, UK

Obstetric medicine2015 Full Text: Link to full Text with Trip Pro

26. Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months?

Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months? BestBets: Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months? Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months? Report By: Chris Morgan - Medical Student Y5 Search checked by Rick Body - Consultant in Emergency Medicine Institution: University of Manchester, Manchester, UK Original institution: Manchester Royal Infirmary Date Submitted: 21st October 2015 (...) Date Completed: 21st October 2015 Last Modified: 21st October 2015 Status: Green (complete) Three Part Question In [patients with proven pulmonary embolism (PE)] is [Rivaroxaban better than warfarin] at [reducing mortality and recurrence of venous thromboembolism at 6 months]? Clinical Scenario A 52-year-old lady has presented to the Emergency Department with a suspected PE. This is confirmed by CT pulmonary angiography (CTPA). Consequently she requires anticoagulation. Hospital guidelines suggest

BestBETS2015

27. Rivaroxaban (Xarelto) - co-administered with aspirin alone or with aspirin plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarker

Rivaroxaban (Xarelto) - co-administered with aspirin alone or with aspirin plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarker

Scottish Medicines Consortium2015

29. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation

Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation 25975659 2015 07 22 2016 04 25 2016 12 15 1522-9645 36 28 2015 Jul 21 European heart journal Eur. Heart J. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. 1805-11 10.1093/eurheartj/ehv177 VENTURE-AF is the first prospective randomized trial of uninterrupted rivaroxaban and vitamin K antagonists (...) (VKAs) in patients with non-valvular atrial fibrillation (NVAF) undergoing catheter ablation (CA). Trial size was administratively set at 250, the protocol-specified target. Events were independently and blindly adjudicated. We randomly assigned 248 NVAF patients to uninterrupted rivaroxaban (20 mg once-daily) or to an uninterrupted VKA prior to CA and for 4 weeks afterwards. The primary endpoint was major bleeding events after CA. Secondary endpoints included thromboembolic events (composite

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

30. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study

Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study 25716463 2015 03 10 2015 08 12 2017 02 20 1553-2712 22 3 2015 Mar Academic emergency medicine : official journal of the Society for Academic Emergency Medicine Acad Emerg Med Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE (...) study. 299-307 10.1111/acem.12615 The objective was to assess adverse outcomes in relation to the simplified Pulmonary Embolism Severity Index (PESI) score in patients treated with rivaroxaban or standard therapy in the phase III EINSTEIN PE study and to evaluate the utility of the simplified PESI score to identify low-risk pulmonary embolism (PE) patients. A post hoc analysis of EINSTEIN PE data was performed to assess the efficacy and safety of rivaroxaban in patients with a range of simplified

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

32. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in

Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in BACKGROUND: Digoxin is a widely used drug for ventricular rate control in patients with atrial fibrillation (AF), despite a scarcity of randomised trial data. We studied the use and outcomes of digoxin in patients in the Rivaroxaban Once Daily

Lancet2015

33. Rivaroxaban (Xarelto)

Rivaroxaban (Xarelto) © 2015 Thrombosis Canada Page 1 of 3 RIVAROXABAN (XARELTO ? ) OBJECTIVE: To provide an overview of the mechanism of action, licensed indications, dosing regimens and side- effects for rivaroxaban. BACKGROUND: Rivaroxaban (Xarelto ? ) is an oral factor Xa inhibitor. By binding reversibly to the active site of factor Xa, rivaroxaban attenuates thrombin generation and reduces fibrin formation. INDICATIONS: Rivaroxaban is currently licensed in Canada for: ? Thromboprophylaxis (...) thereafter. ? Rivaroxaban should not be used in patients with a CrCl 50 mL/min or 15 mg OD for those with CrCl 30-49 mL/min. MONITORING: Routine laboratory monitoring is unnecessary. Although the prothrombin time/international normalized ratio (PT/INR) and activated partial thromboplastin time (aPTT) do not provide reliable measures of rivaroxaban’s anticoagulant activity, the prothrombin time is more responsive. Anti- factor Xa assays using rivaroxaban calibrators, where available, can be used

Thrombosis Interest Group of Canada2015

34. In nonvalvular atrial fibrillation, effects of rivaroxaban compared with warfarin did not differ by patient age

In nonvalvular atrial fibrillation, effects of rivaroxaban compared with warfarin did not differ by patient age 25402538 2014 11 18 2015 04 14 2016 10 25 1539-3704 161 10 2014 Nov 18 Annals of internal medicine Ann. Intern. Med. ACP Journal Club: in nonvalvular atrial fibrillation, effects of rivaroxaban compared with warfarin did not differ by patient age. JC5 10.7326/0003-4819-161-10-201411180-02005 Rondina Matthew M eng K23 HL092161 HL NHLBI NIH HHS United States R01 AG048022 AG NIA NIH HHS

Annals of Internal Medicine2014 Full Text: Link to full Text with Trip Pro

35. Rivaroxaban 2.5 mg (Xarelto): no justification for using this anticoagulant after an acute coronary syndrome

Rivaroxaban 2.5 mg (Xarelto): no justification for using this anticoagulant after an acute coronary syndrome Prescrire IN ENGLISH - Spotlight ''Rivaroxaban 2.5 mg (Xarelto°): no justification for using this anticoagulant after an acute coronary syndrome'', 1 October 2014 {1} {1} {1} | | > > > Rivaroxaban 2.5 mg (Xarelto°): no justification for using this anticoagulant after an acute coronary syndrome Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |  (...)  |   |   |   |   |   |   |   |  Spotlight Rivaroxaban 2.5 mg (Xarelto°): no justification for using this anticoagulant after an acute coronary syndrome FEATURED REVIEW It has not been demonstrated that adding rivaroxaban to aspirin alone or to aspirin plus clopidogrel benefits patients who have had an acute coronary syndrome. The risk of serious and fatal bleeds is probably underestimated. Caution dictates that rivaroxaban should

Prescrire2014

36. Apixaban and rivaroxaban for stroke prevention in atrial fibrillation: safety

Apixaban and rivaroxaban for stroke prevention in atrial fibrillation: safety Apixaban and rivaroxaban for stroke prevention in atrial fibrillation: safety Apixaban and rivaroxaban for stroke prevention in atrial fibrillation: safety CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Apixaban and rivaroxaban for stroke (...) prevention in atrial fibrillation: safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Reference List. 2014 Authors' conclusions Twenty-two systematic reviews/meta-analyses, 24 randomized controlled trials, and three non-randomized studies were identified regarding adverse events associated with the use of apixaban and rivaroxaban. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Anticoagulants; Atrial Fibrillation; Humans; Morpholines

Health Technology Assessment (HTA) Database.2014

37. Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism

Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary (...) embolism. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC final recommendation. 2014 Authors' conclusions CDEC recommends that rivaroxaban be listed for the treatment of VTE (DVT and PE) and prevention of recurrent DVT and PE, for a duration of up to six months. If treatment is to be extended beyond six months, the following condition must be met. Condition: A reduction in price is required if rivaroxaban is funded for a treatment duration of more than six months. Final publication

Health Technology Assessment (HTA) Database.2014

38. Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience

Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience Prescrire IN ENGLISH - Spotlight ''Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience '', 1 June 2013 {1} {1} {1} | | > > > Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |    (...) |   |   |   |  Spotlight Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience FEATURED REVIEW Dabigatran, rivaroxaban and apixaban are oral anticoagulants used to prevent or treat thrombosis. Difficulties in the management of bleeding weigh heavily in the balance of potential harm versus potential benefit of these drugs. Full review (5 pages) available for download by subscribers. Abstract Dabigatran, rivaroxaban and apixaban

Prescrire2014

39. Rivaroxaban - Thromboembolic events (venous), pulmonary embolism

Rivaroxaban - Thromboembolic events (venous), pulmonary embolism Common Drug Review CDEC Meetings: October 16, 2013; January 15, 2013; March 19, 2014 Notice of Final Recommendation — March 26, 2014 Page 1 of 6 © 2014 CADTH CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto — Bayer Inc.) New Indication: Pulmonary Embolism Recommendation: CDEC recommends that rivaroxaban be listed for the treatment of VTE (DVT and PE) and prevention of recurrent DVT and PE, for a duration of up to six months (...) . If treatment is to be extended beyond six months, the following condition must be met: Condition: ? A reduction in price is required if rivaroxaban is funded for a treatment duration of more than six months. Reason for the Recommendation: 1. In one randomized controlled trial (RCT) involving patients with acute PE (EINSTEIN-PE), rivaroxaban was reported to be non-inferior to a regimen of enoxaparin plus a vitamin K antagonist (VKA) based on the incidence of recurrent DVT, non-fatal PE, or fatal PE. Given

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2014

40. Apixaban and Rivaroxaban for Stroke Prevention in Atrial Fibrillation

Apixaban and Rivaroxaban for Stroke Prevention in Atrial Fibrillation Title: Apixaban and Rivaroxaban for Stroke Prevention in Atrial Fibrillation: Safety DATE: 28 March 2014 RESEARCH QUESTIONS 1. What are the adverse events associated with the use of apixaban? 2. What are the adverse events associated with the use of rivaroxaban? KEY MESSAGE Twenty-two systematic reviews/meta-analyses, 24 randomized controlled trials, and three non- randomized studies were identified regarding adverse events (...) associated with the use of apixaban and rivaroxaban. METHODS A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2014, Issue 3), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. Methodological filters were applied to limit retrieval to safety data. Where possible, retrieval was limited to the human population. The search was also limited

Canadian Agency for Drugs and Technologies in Health - Rapid Review2014